Manipulating the indigenous microbiota in humans: Prebiotics, probiotics, and synbiotics

The Human Microbiota: How Microbial Communities Affect Health and Disease

Volumn , Issue , 2013, Pages 315-338

  Macfarlane, George T ^a   Macfarlane, Sandra ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Bifidobacteria; Indigenous microbiota; Inflammatory bowel disease; Large intestine; Prebiotics; Probiotics; Synbiotics

Indexed keywords

EID: 84952779002     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118409855.ch14     Document Type: Chapter

References (99)

1. Cummings JH, Macfarlane GT. Colonic microflora: Nutrition and health. Nutrition 13:476-478 (1997).
2. Gibson GR, Macfarlane S, Macfarlane GT. Metabolic interactions involving sulphatereducing and methanogenic bacteria in the human large intestine. FEMS Microbiol Ecol 12:117-125 (1993).
3. Degnan BA, Macfarlane GT. Arabinogalactan utilization in continuous cultures of Bifi-dobacterium longum:Effect of co-culture with Bacteroides thetaiotaomicron. Anaerobe 1:103-112 (1995).
4. Parker RB. Probiotics, the other half of the antibiotic story Animal Nutr Health 29:4-8 (1974).
5. FAO. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO Working Group, London, Ontario, Canada, 4/30-5/1/02. In Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation, FAO Food and Nutrition Paper 85, Rome, 2006, pp. 1-56.
6. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 15:501-506 (2002).
7. Prantera C, Sribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence of after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG Gut 51:405-409 (2002).
8. Zocco MA, Zileri Dal Verne L, Armuzzi A, Nista EC, Papa A, Candelli M. Comparison of Lactobacillus GG and mesalazine inmaintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology 124 (4 Suppl 1): A201 (2003).
9. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease Inflamm Bowel Dis 11:833-839 (2005).
10. Marteau P, Lehman M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soule JC, Bourreille A, Metman E, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence of Crohn's disease: A randomised, double-blind, placebo controlled GETAID trial Gut 55:842-847 (2006).
11. Van Gossum A, Dewit O, Louis E, de Hergtogh G, Baert F, Fontaine F, Devos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection Inflamm Bowel Dis 13:135-142 (2007).
12. Malchow HA. Crohn's disease and Escherichia coli-a new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25:653-858 (1997).
13. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease Digest Dis Sci 45:1462-1464 (2000).
14. Campieri M, Rizzello F, Venturi A, Poggili G, Ugolini F, Helwig U. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study versus mezalamine. Gastroenterology 118 (4 Suppl 2): A781 (2000).
15. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A metaanalysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease Digest Dis Sci 53:2524-2531 (2008).
16. Krius W, Scutz E, Fric P, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesasalazine in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 11:853-858 (1997).
17. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial Lancet 354:635-639 (1999).
18. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut 53:1617-1623 (2004).
19. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation:preliminary data on maintenance treatment of patients with ulcerative colitis Aliment Pharmacol Ther 13:1103-1108 (1999).
20. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Stalano A. Effect of a probiotic preparation (VSL3) on induction and maintenance of remission in children with ulcerative colitis Am J Gastroenterol 104:437-443 (2009).
21. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol 15:697-698 (2003).
22. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22:56-63 (2003).
23. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, Liu YH, Dan HL, Jian YT, Chen XQ. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis World J Gastroenterol 10:1521-1525 (2004).
24. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 23:1567-1574 (2006).
25. Shanahan F, Guarner F, von Wright A, Vilpponene-Salmela T, O'Donoghue D, Kiely B. A one year, randomised, double blind, placebo controlled trial of a lactobacillus or a bifidobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 130 (S2): A44 (2006).
26. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD005573 (2007).
27. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial Gastroenterology 119:305-309 (2000).
28. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigandi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial Gastroenterology 124:1202-1209 (2003).
29. Mimura T, Rizzullo F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis Gut 53:108-114 (2004).
30. Carter MJ, Lobo AJ, Travis SPL, on behalf of the IBD section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults Gut 53:v1-v16 (2004).
31. Gosselink MP, Schouten WR, Van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhanmnosus GG Dis Colon Rectum 47:876-884 (2004).
32. Hunter J, Lee A, King T, Barratt M, Linggood M, Blades J. Enterococcus faecium strain PR88-an effective probiotic Gut 38:A62 (1996).
33. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome Digest Dis Sci 47:2615-2620 (2002).
34. Baussermann M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial J Pediatr 147:197-201 (2005).
35. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children Aliment Pharmacol Ther 25:177-184 (2007).
36. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention Aliment Pharmacol Ther 22:387-394 (2005).
37. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review Am J Gastroenterol 104:1033-1049 (2009).
38. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome Am J Gastroenterol 101:1581-1590 (2006).
39. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii:A prospective study. Gastroenterology 96:981-988 (1989).
40. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo Am J Gastroenterol 90:439-448 (1995).
41. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients J Infect 36:171-174 (1998).
42. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. 67:302-307 (1999).
43. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease Am J Gastroenterol 101:812-822 (2006).
44. Siitonin S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola AL. Effect of Lactobacillus GG yogurt in prevention of antibiotic associated diarrhoea Ann Med 22:57-59 (1990).
45. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized placebo-controlled trail Mayo Clin Proc 76:883-889 (2001).
46. Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study Pediatrics 104:64-67 (1999).
47. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-assocaiated diarrhea in children J Pediatr 135:564-568 (1999).
48. Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G. Meta-analysis:The effects of probiotic administration on antibiotic-associated diarrhoea Aliment Pharmacol Ther 16:1461-1467 (2002).
49. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in prevention of antibiotic associated diarrhea in children: A meta-analysis of randomized controlled trials. J Pediatr 149:367-372 (2006).
50. Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea Cochrane Database Syst Rev 2:CD004827 (2007).
51. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections Anaerobe 15:274-280 (2009).
52. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: A multicenter European trial J Pediatr Gastroenterol Nutr 30:54-60 (2000).
53. Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea J Pediatr Gastroenterol Nutr 25:516-519 (1997).
54. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Milolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants J Pediatr 138:361-365 (2001).
55. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children Aliment Pharmacol Ther 25:257-264 (2007).
56. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus Lancet 344:1046-1049 (1994).
57. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis J Pediatr Gastroenterol Nutr 20:333-338 (1995).
58. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children Aliment Pharmacol Ther 25:871-881 (2007).
59. Szajewska H, Skorka A. Saccharomyces boulardii for treating acute gastroenteritis in children: Updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther 30:960-961 (2009).
60. Guarino A, Albino F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H. European Society for Pediatric Gastroenterology, Hepatology and Nutrition/European Society for Pediatric Infectious Diseaeses evidence-based guidelines for the management of acute gastroenteritis in children in Europe J Pediatr Gastroenterol Nutr 46:S81-S122 (2008).
61. Coccorullo P, Strisciuglio C, Martinelli M, Miele E, Greco L, Staiano A. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: A double-blind, randomized, placcebo-controlled study J Pediatr 157:589-602 (2010).
62. Agrawal A, Houghton LA, Morris J, Reilly BD, Guyonnet D, Goupil-Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ. Clinical trial: The effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29:104-114 (2008).
63. Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C. Review article:"Bifidobacteria as probiotic agents:" physiological effects and clinical benefits Aliment Pharmacol Ther 22:495-512 (2005).
64. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation World J Gastroenterol 16:69-75 (2010).
65. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotic in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357:1076-1079 (2001).
66. Kalliomaki M, Salminen S, Poussa T, Arvilonmi H, Isolari E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 361:1869-1871 (2003).
67. Abrahamsson TR, Jakobsson T, Bottcher MF, Fredrikson M, Jenmalm MC, Bjorksten B, Oldaeus G. Probiotics in prevention of IgE-associated eczema: A double-blind, randomized placebo-controlled trial J Allergy Clin Immunol 119:1174-1180 (2007).
68. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebocontrolled trial of probiotics for primary preventiomn: No clinical effects of Lactobacillus GG supplementation Pediatrics 121:e850-e856 (2008).
69. Niers L, Martin R, Rijkers G, Sengers F, Timmerman H, van Uden N, Smidt H, Kimpen J, Hoekstra M. The effects of selected probiotic strains on the development of eczema Allergy 64:1349-1358 (2009).
70. Lee J. Seto D, Biewlory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis J Allergy Clin Immunol 121:116-121 (2008).
71. Majamaa H, Isolauri E. Probiotics: A novel approach in the management of food allergy J Allergy Clin Immunol 99:179-185 (1997).
72. Isolauri E, Arvola T, Sutas Y, Moilanaen E, Salminen S. Probiotics in the management of atopic eczema Clin Exp Allergy 30:1604-1610 (2000).
73. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in children with atopic dermatitis J Allergy Clin Immunol 111:389-395 (2003).
74. Boyle RJ, Bath-Hextall FJ, Leonarsi-Bee J, Murrell DF, Tang MLK. Probiotics for treating eczema Cochrane Database Syst Rev 4:CD006135 (2008).
75. Betsi GI, Papadavid E, Falagas ME. Probiotics for the prevention and treatment of atopic dermatitis: A review of the evidence from randomized controlled trials. Am J Clin Dermatol 9:93-103 (2008).
76. Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019 Am J Clin Nutr 74:833-839 (2001).
77. Pineiro M, Asp NG, Reid G, Macfarlane S, Morelli L, Brunser O, Tuohy K. FAO Technical Meeting on Prebiotics J Clin Gastroenterol 42:S156-S159 (2008).
78. Macfarlane S, Macfarlane GT, Cummings JH. Prebiotics in the gastrointestinal tract Aliment Pharmacol Ther 24:701-714 (2006).
79. Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics J Appl Microbiol 104:305-344 (2008).
80. Cummings JH, Pomare EW, Branch WJ, Naylor CPE, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood Gut 28:1221-1227 (1987).
81. Macfarlane GT, Macfarlane S. Fermentation in the human large intestine, its physiological consequences and the potential contribution of prebiotics J Clin Gastroenterol 45:120-127 (2011).
82. Macfarlane S, Steed H, Macfarlane GT. Intestinal bacteria in inflammatory bowel disease Crit Rev in Clin Lab Sci 46:25-54 (2009).
83. Steed H, Macfarlane GT, Macfarlane S. Prebiotics, synbiotics and inflammatory bowel disease Mol Nutr Food Res 52:898-205 (2008).
84. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum / Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54:242-249 (2005).
85. Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis Clin Infect Dis 38:1690-1699 (2004).
86. Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings J, Macfarlane S. Clinical trial: The microbiological and immunological effects of synbiotic consumption-a randomized double-blind placebo-controlled study in active Crohn's disease Aliment Pharmacol Ther 32:872-883 (2010).
87. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, Tanaka R, Otani T. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study Digestion 84:128-133 (2011).
88. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease Dig Dis Sci 52:385-389 (2007).
89. Vandenplas Y, De Hert SG ; PROBIOTICAL-study group. Randomised clinical trial: The synbiotic food supplement Probiotical vs. placebo for acute gastroenteritis in children Aliment Pharmacol Ther 34:862-867 (2011).
90. Puccio G, Caiozzo C, Meli F, Rochat F, Grathwohl D, Steenhout P. Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL99 and prebiotics Nutrition 23:1-8 (2007).
91. Fateh R, Iravani S, Frootan M, Rasouli MR, Saadat S. Synbiotic preparation in men suffering from functional constipation: A randomized controlled trial. Swiss Med Wkly 30:141 (2011).
92. Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: Two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy 61:431-437 (2006).
93. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Turre T, Kuitunen M. Probiotics and pre-biotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, placebo-controlled trial. J Allergy Clin Immunol 119 :192-198 (2007).
94. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Turre T, Kuitunen M. Long-term safety impact on infection rates of postnatal probiotic and prebiotic(synbiotic) treatment: Randomized, double-blind, placebo-controlled trial. Pediatrics 122:8-12 (2008).
95. Van der Aa LB, Heymans HS, van Aalderen WM, Sillevis Smitt JH, Knol J, Ben Amor K, Goossens DA, Sprikkelman AB ; Synbad Study Group. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial Clin Exp Allergy 5:795-804 (2010).
96. Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide for treating children with moderate to severe atopic dermatitis:A double-blind randomized clinical trial of efficacy and safety Br J Dermatol 1:129-136 (2012).
97. Bartosch S, Woodmansey EJ, Paterson JC, McMurdo MEM, Macfarlane GT. Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis and oligofructose in elderly patients, determined by real-time polymerase chain reaction and counting of viable bacteria Clin Infect Dis 40:28-37 (2005).
98. Ouwehand AC, Tiihonen K, Saarinen M, Putalaa H, Rautonen N. Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: Intestinal and immune parameters Br J Nutr 101:367-375 (2009).
99. Metchnikoff E. The Prolongation of Life, Heinemann, London, 1907.